SG Americas Securities LLC Grows Stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

SG Americas Securities LLC raised its stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 61.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,270 shares of the company’s stock after acquiring an additional 15,777 shares during the period. SG Americas Securities LLC’s holdings in Tenaya Therapeutics were worth $59,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Tenaya Therapeutics by 204.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after purchasing an additional 226,466 shares in the last quarter. abrdn plc bought a new position in shares of Tenaya Therapeutics during the third quarter valued at $1,063,000. State Street Corp lifted its holdings in shares of Tenaya Therapeutics by 0.9% during the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock valued at $2,044,000 after purchasing an additional 9,506 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Tenaya Therapeutics by 5.4% during the third quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock valued at $2,502,000 after purchasing an additional 66,968 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after purchasing an additional 16,687 shares in the last quarter. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics Stock Performance

TNYA stock opened at $0.95 on Friday. Tenaya Therapeutics, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $7.01. The business’s 50-day moving average is $1.58 and its two-hundred day moving average is $2.13. The company has a market cap of $75.03 million, a price-to-earnings ratio of -0.66 and a beta of 2.84.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TNYA. Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Tenaya Therapeutics in a report on Friday, October 18th. Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a report on Monday, February 3rd. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $17.33.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.